Journal article
Botulinum Toxin Type B for Treatment of Spasmodic Dysphonia: A Case Report
Journal of voice, v 16(3), pp 422-424
2002
PMID: 12395995
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.
Metrics
Details
- Title
- Botulinum Toxin Type B for Treatment of Spasmodic Dysphonia: A Case Report
- Creators
- Robert Thayer Sataloff - Thomas Jefferson UniversityYolanda D. Heman-Ackah - University of Illinois ChicagoLance L. Simpson - Thomas Jefferson UniversityJong-Beak Park - Thomas Jefferson UniversityAmy Zwislewski - American Institute for Voice and Ear ResearchCaren Sokolow - American Institute for Voice and Ear ResearchSteven Mandel - Thomas Jefferson University
- Publication Details
- Journal of voice, v 16(3), pp 422-424
- Publisher
- Mosby, Inc
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine; Otolaryngology (and Head and Neck Surgery)
- Web of Science ID
- WOS:000181346900014
- Scopus ID
- 2-s2.0-0036727670
- Other Identifier
- 991019312433104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Audiology & Speech-language Pathology
- Otorhinolaryngology